Liraglutide significantly improved glucose tolerance, body weight, and other cardiometabolic disturbances in clozapine- or olanzapine-treated patients who have disorders on the schizophrenia spectrum, according to research presented at the American Diabetes Association 77th Scientific Sessions, held June 9-13 in San Diego, California.
Although patients with schizophrenia have higher mortality rates compared with the background population (primarily caused by cardiovascular disease), interventions seeking to counteract antipsychotic-induced weight gain and cardiometabolic disturbances have had limited success.
4 Likes